Trials / Completed
CompletedNCT00670592
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCD122 |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2008-05-02
- Last updated
- 2020-12-17
Locations
28 sites across 11 countries: United States, Australia, Belgium, Canada, France, Germany, Hong Kong, Italy, Singapore, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT00670592. Inclusion in this directory is not an endorsement.